Table 3.
| PAC | PRA | PAC/PRA | |
|---|---|---|---|
| Medications | |||
| β-Adrenergic blockers | ↓ | ↓↓ | ↑(FP) |
| Central α-2 agonists | ↓ | ↓↓ | ↑(FP) |
| NSAIDs | ↓ | ↓↓ | ↑(FP) |
| K+-wasting diuretics | →↑ | ↑↑ | ↓(FN) |
| K+-sparing diuretics | ↑ | ↑↑ | ↓(FN) |
| ACE inhibitors | ↓ | ↑↑ | ↓(FN) |
| ARBs | ↓ | ↑↑ | ↓(FN) |
| Ca2+ blockers (DHPs) | →↓ | ↑ | ↓(FN) |
| Renin inhibitors | ↓ | ↓↑1 | ↑(FP)1 |
| ↓ (FN) 1 | |||
| Potassium status | |||
| Hypokalemia | ↓ | →↑ | ↓(FN) |
| Potassium loading | ↑ | →↓ | ↑(FP) |
| Dietary sodium | |||
| Sodium restricted | ↑ | ↑↑ | ↓(FN) |
| Sodium loaded | ↓ | ↓↓ | ↑(FP) |
| Advancing age | ↓ | ↓↓ | ↑ (FP) |
| Other conditions | |||
| Renal impairment | → | ↓ | ↑(FP) |
| PHA-2 | → | ↓ | ↑(FP) |
| Pregnancy | ↑ | ↑↑ | ↓(FN) |
| Renovascular HTN | ↑ | ↑↑ | ↓(FN) |
| Malignant HTN | ↑ | ↑↑ | ↓ (FN) |